Company Overview

Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies and other genomic medicines. The company operates primarily within the biotechnology, gene editing, and genetic medicine industries, with research efforts centered on treating serious diseases through targeted genome engineering. Precision BioSciences is best known for its proprietary ARCUS genome editing platform, a gene editing technology derived from a naturally occurring homing endonuclease. The company’s development programs have historically focused on immuno-oncology, genetic diseases, and hepatitis B, although its strategic emphasis has increasingly shifted toward in vivo gene editing applications.

The company generates value primarily through research and development partnerships, licensing arrangements, and advancement of proprietary therapeutic candidates. Precision BioSciences has collaborated with larger pharmaceutical and biotechnology companies to support development and commercialization efforts. Founded in 2006 and headquartered in Durham, North Carolina, the company evolved from an early-stage genome engineering platform developer into a publicly traded biotechnology company listed on Nasdaq under the ticker DTIL. Over time, the company has narrowed its operational focus to prioritize programs with potential for differentiated therapeutic delivery and editing precision.

Business Operations

Precision BioSciences organizes its operations around development programs leveraging its ARCUS technology platform. Historically, the company operated programs across three major areas: allogeneic CAR T cell therapies, in vivo gene editing, and infectious disease applications. In recent years, public filings and investor materials indicate that the company has prioritized in vivo gene editing programs targeting liver-directed diseases and other genetic disorders while reducing investment in certain oncology programs. Revenue has primarily been derived from collaboration agreements, milestone payments, licensing arrangements, and research funding rather than commercialized product sales.

The company’s operations are concentrated mainly in the United States, though its partnerships and intellectual property activities have international relevance. Precision BioSciences controls a portfolio of genome editing patents and proprietary engineering capabilities associated with the ARCUS platform. The company has previously announced collaborations with organizations including Eli Lilly and Company and other biotechnology partners for specific research and development initiatives. Data regarding certain legacy partnerships and program continuation status is inconclusive based on available public sources because some agreements have been restructured, deprioritized, or terminated over time.

Strategic Position & Investments

Precision BioSciences’ strategic direction has increasingly emphasized capital-efficient development of in vivo gene editing therapeutics using the ARCUS platform. Company disclosures indicate a focus on developing therapies that can potentially provide durable therapeutic outcomes through highly specific genomic modifications. Management has also highlighted differentiation through the comparatively smaller size of ARCUS nucleases, which may offer advantages for delivery using viral vectors such as adeno-associated viruses (AAVs). Strategic prioritization has included streamlining operations, reducing expenditures on non-core programs, and concentrating resources on selected clinical and preclinical assets.

The company has pursued external collaborations and licensing agreements to support funding and accelerate development. Precision BioSciences previously advanced allogeneic CAR T programs through its Precigen-related historical relationships and other collaborations, though several oncology initiatives have been reduced or discontinued as part of strategic restructuring. Public disclosures also indicate ongoing evaluation of additional partnership opportunities involving gene editing technologies and intellectual property licensing. Data regarding future acquisition activity or major long-term investment commitments remains inconclusive based on available public sources.

Geographic Footprint

Precision BioSciences is headquartered in Durham, North Carolina, within the biotechnology and life sciences cluster associated with the Research Triangle region of the United States. The company’s primary laboratory, research, and administrative operations are based in the U.S., and its clinical development activities are largely conducted through domestic and international clinical research networks and contractors.

While Precision BioSciences does not maintain the extensive multinational commercial infrastructure typical of large pharmaceutical companies, its technologies and partnerships have international relevance through licensing agreements, intellectual property protections, and global clinical development pathways. The company’s operational influence extends primarily across North America and selected international markets involved in biotechnology research, regulatory engagement, and clinical trial activity.

Leadership & Governance

Precision BioSciences was founded by researchers associated with genome engineering and molecular biology innovation, and the company has maintained a science-driven governance structure emphasizing platform development and translational medicine. Leadership communications in public filings and investor presentations have consistently emphasized disciplined capital allocation, platform differentiation, and development of potentially curative therapies using genome editing technologies.

Key executives and leadership figures include:

• Michael Amoroso – President and Chief Executive Officer
• R. Nolan Townsend, III – Chief Financial Officer
• Cindy Atwell – Chief Development and Business Officer
• Jeff Smith – Chief Research Officer
• Matthew Kane, J.D. – Chief Business Officer and General Counsel

The company’s board and executive leadership have experience spanning biotechnology research, pharmaceutical development, finance, regulatory affairs, and corporate strategy. Governance practices and executive responsibilities are described in company filings including annual reports and proxy statements filed with the U.S. Securities and Exchange Commission (SEC).